Skip to main content

Table 1 Basic characteristics of patients with primary systemic therapy

From: Presence of apoptotic and nonapoptotic disseminated tumor cells reflects the response to neoadjuvant systemic therapy in breast cancer

Characteristic n Bone marrow positive P value
   n %  
Total 157 84 53 -
Menopausal status     0.3
   Premenopausal 72 42 58  
   Postmenopausal 85 42 49  
Tumor size     0.6
   ypT0 24 10 44  
   ypT1 61 33 54  
   ypT2–ypT4 73 41 56  
Nodal status     0.5
   ypN negative 75 38 51  
   ypN positive 82 46 56  
Estrogen receptor status     1.0
   Negative 39 21 54  
   Positive 118 63 53  
Progesterone receptor status     0.7
   Negative 68 35 52  
   Positive 89 49 55  
HER2 status     
   Negative (score 0/+1 by immunohistochemistry) 115 63 54 0.7
   Positive (score +2/+3 by immunohistochemistry) 39 20 51  
Grading     0.9
   I–II 109 58 53  
   III 41 21 51  
Histology     0.2
   Ductal 97 48 49  
   Lobular 33 17 52  
   Others 27 19 70  
Primary systemic therapy     0.3
   Chemotherapy 142 78 55  
   Hormonal therapy 15 6 40  
Response to neoadjuvant systemic therapya     <0.05c
   Pathological complete remission 24 10 (4)b 42 (17)b  
   Partial remissiond 87 42 (11)b 48 (13)b  
   Stable disease 40 27 (2)b 68 (5)b  
   Progressive disease 5 4 (0)b 80 (0)b  
  1. aNot including apoptotic cells (see Table 2). bNumber (percentage) of patients with only apoptotic cells. cComplete remission + partial remission (46%) versus stable disease + progressive disease (69%). dPartial remission also includes patients with clinical complete remission but pathological partial remission.
\